Skip to main content

Burnham Institute to Build Facility in Orlando; Functional Genomics Will Be One Focus

NEW YORK (GenomeWeb News) – The Burnham Institute for Medical Research yesterday said it plans to establish a research facility in Orlando, Fla., giving the California-based nonprofit a presence on both US coasts.
The institute said it plans to build a 300-person operation in Orlando to help it expand its capabilities in chemistry, pharmacology, and functional genomics in its study of cancer, degenerative diseases, and infectious diseases.
The Burnham said the Florida move will also enable it to expand its research focus into diabetes and obesity research.
The institute said it will develop the facility through a partnership with the State of Florida, Orange County, the City of Orlando, the University of Central Florida, the University of Florida, the Tavistock Group, and Florida's philanthropic community.
"One of the attractions for our organization in expanding operations to Florida was the tremendous support and encouragement we received from Florida's universities,” John Reed, president and CEO of the Burnham, said in a statement. “In particular, the University of Florida and the University of Central Florida provided strong incentives, including adjunct faculty positions for many of the scientists we recruit to Orlando.”
The Burnham will continue to develop new research initiatives at its current site in La Jolla, Calif., where it plans to grow from 750 to 900 employees over the next five years.
It was not immediately clear when the institute would begin building the facility or when it would be up and running. Calls to the Burnham were not immediately returned.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.